Company | Page 52 of 71 | SpiritIndia.com

Optical Lens :: New wide-angle lens produces pictures without distortion

South Korean researchers have designed and built an inexpensive optical lens that collects light from a large area and produces a virtually distortion-free wide-angle image. Standing in contrast to commonly known “fisheye” lenses, which produce significant amounts of visual distortion, low-distortion wide-angle lenses can potentially improve image-based applications such as security-camera systems and robot navigation. The research appears in the December 1 issue of Applied Optics, a publication of the Optical Society of America.

Erectile Dysfunction :: Study of gene transfer for erectile dysfunction shows promise

The first human study using gene transfer to treat erectile dysfunction (ED) shows promising results and suggests the potential for using the technology to treat overactive bladder, irritable bowel syndrome and asthma, according to the researchers.

Back Pain :: One-off treatment to stop back pain – Using patients’ own stem cells

A University of Manchester researcher has developed a treatment for lower back pain using the patient’s own stem cells, which could replace the use of strong painkillers or surgery that can cause debilitation, neither of which addresses the underlying cause.

Heart Attack :: Scientists work to identify genes that contribute to early heart attack risk

Scientists at Wake Forest University Baptist Medical Center and colleagues at four other medical centers have launched a $10 million multi-year study to identify genes that may contribute to early atherosclerosis.

Heart Disease :: Barr’s Subsidiary PLIVA Receives Approval for Pravastatin Tablets

Barr Pharmaceuticals, Inc. (NYSE: BRL) and its subsidiary PLIVA d.d. (LSE: PLVD; ZSE: PLVA-R-A) today announced that PLIVA has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to manufacture and market Pravastatin Tablets 10mg, 20mg, and 40mg, the generic version of Bristol-Myers Squibb’s PRAVACHOL(R) (Pravastatin Sodium) Tablets. The Company plans to launch its product immediately. PLIVA has also received tentative approval for its Pravastatin Tablets 80mg strength and plans to launch this strength following the expiration of a competitor’s 180-day generic drug exclusivity period and subsequent final approval of PLIVA’s application.

HIV :: Bristol-Myers Squibb & National AIDS Fund announce World AIDS Day Campaign

Bristol-Myers Squibb Company (NYSE: BMY) in cooperation with the National AIDS Fund today launched the third annual “Light to Unite” campaign in support of World AIDS Day. This year’s “Light to Unite” program shines a light on the devastating impact of the HIV/AIDS epidemic in underserved communities throughout the United States. Bristol-Myers Squibb and the National AIDS Fund are encouraging people across the country to visit http://www.lighttounite.org/ to show their support and to educate themselves and others on emerging HIV/AIDS issues within diverse communities across the U.S.

Breast Cancer :: Aeterna Zentaris – Positive Top Line Phase 1 Results for AN-152 in Gynaecological and Breast Cancers

?terna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today disclosed additional positive top line Phase 1 results for its cytotoxic conjugate AN-152 in patients with gynaecological and breast cancers. Further data showed the compound?s good safety profile and established the maximum tolerated dose (MTD) at 267 mg/m? which will be the recommended dose for a Phase 2 trial. In addition to good safety data, the trial provided a hint of efficacy as disease stabilization and regression of lesions were observed at the 160 mg/m? and 267 mg/m? dose levels.

HIV :: Boehringer Ingelheim’s patent rights are no obstacle to access to ARV drugs in developing countries

On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune (nevirapine) do not prevent access to this medication in low income countries.

Healthcare :: GE Healthcare Re-Imagines Radiology at RSNA Conference

GE Healthcare, a unit of General Electric Company (NYSE:GE), today kicked off its participation in the 2006 Radiological Society of North America (RSNA) conference in Chicago with a focus on the company?s ‘Radiology Re-imagined’ theme along prominent displays of breakthough products that highlight the company?s exhibit booth.

Diet :: HoneyBaked Foods recalls hams & turkeys

USDA has issued a recall of HoneyBaked Foods, Inc., of Toledo Ohio, HoneyBaked Hams and Sliced & Glazed Turkeys purchased from September 5 through November 13, 2006, at its retail location at 6145 Merger Drive in Toledo and at three kiosks in Toledo, Maumee and Woodville, Ohio.